The AstraZeneca share price is at all-time highs. Should investors be wary?

Shares of AstraZeneca plc (LON: AZN) look too expensive to me right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Amid a choppy market environment, shares of AstraZeneca (LSE: AZN) are performing extremely well. But is this a reason to buy them at their current price? Let’s examine the reasons behind the stock’s performance, as well as whether the current valuation represents an attractive investment opportunity.

Recent successes

Although the last year was an up and down period for AstraZeneca shareholders, patient investors were rewarded with a strong trading update in July. Priced at 7,327p a share, the stock is currently trading at all-time highs, and it’s easy to see why. Product sales were up 17% in the first half of 2019, and total revenue increased by 14%. 

Both revenue and earnings per share beat analysts’ expectations — the former by $251m (£207m) and the latter by $0.13/share (£0.11/share). This outperformance has driven the stock higher by over 15% since the release of the earnings report. 

Drug sales are on the rise

Over the last few years, AstraZeneca has been increasing its investment in its oncology division, and these trading results are evidence of that. Revenue from the oncology segment as a whole grew by 58% in the first half of 2019. These increases were led by lung cancer drug Tagrisso (£1.16 bn) and ovarian cancer treatment Lynparza (£429m), as well as Imfinzi (£547m), prescribed for bladder and urinary tract cancers. 

A few months ago I wrote that CEO Pascal Soriot deserves a lot of credit for AstraZeneca’s much-improved results. It was his vision to move the company to focus on oncology treatment, and this strategy seems to be bearing fruit. Nevertheless, I believe that from an investment standpoint, the business is just too expensive to buy.

Too rich for my blood

Shares of AstraZeneca currently trade at a forward price-to-earnings ratio of 24, well above the PE ratio for the FTSE 100 as a whole, which stands at 15.6. Moreover, it yields a dividend of 3.18%, which is also below the FTSE 100 average (4.74%). And as my colleague Roland Head points out, the company’s net debt has risen significantly over the last four years — from £6.43bn to £13.44bn. He believes that management’s desire to maintain the dividend at current levels has forced it to rely on debt to fund investment, and I agree.

Companies that have above-average valuations tend to underperform, statistically speaking. This is particularly true in times of higher volatility, as has been the case in recent months. When everything is falling, those who bought highest will suffer the most pain. 

There is also the nagging uncertainty surrounding how Brexit will affect the entire pharmaceutical industry. If a no-deal scenario does materialise, that could seriously impact the ability of AstraZeneca (and other companies in the sector) to export drugs to the European Union. I believe that the market is not accurately pricing in this possibility, and for these reasons I’ll be staying away from this stock. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stepan Lavrouk owns no shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »